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Questions 
• Classification of Hepatic Encephalopathy 
– Covert vs Minimal 
– The brain in ACLF 
• Pathogenesis of HE 
– Ammonia and Inflammation  
• New concepts of underlying mechanisms 
– Involvement of different inflammatory cell types in HE 
• Why may HE increase the risk of death of cirrhotic 
patients? 
• Is HE truly reversible? 
• Interorgan ammonia metabolism: The basis of novel 
therapies of HE 
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Classification of HE: Clarification or 
Confusion? 
Vilstrup et al. J Hepatol 2014 
One disease or two? 
Patients 
  
  
Unimpaired 
n=23 
 
mHE 
n=39 
 
Grade 1 HE 
n=44 
 
Age (year) 59 ± 6 58 ± 10 58 ± 12 
MELD 15 ± 6 14 ± 6 16 ± 6 
Albumin (g/dL) 2.8 ± 0.7 2.9 ± 0.5 2.9 ± 0.5 
Ammonia (mol/L) 48 ± 11 61 ± 14* 62 ± 12* 
Sodium (mmol/L) 136 ± 5 136 ± 6 135 ± 5 
Creatinine (mol/L) 91 ± 60 69 ± 39 81 ± 43 
WBC count (x 109/L) 5.0 ± 2.2 6.5 ± 3.1 7.4 ± 4.8 
*p<0.05 compared with unimpaired 
Thomsen et al. Plosone 2016 
Mortality 
Thomsen et al. Plosone 2016 
Complications requiring hospitalisations 
  
  
Unimpaired 
n=23 
mHE 
n=39 
Grade 1 HE 
n=44 
Infections n (%) 2 (9) 7 (18) 15 (34) 
HE n (%) 1 (4) 3 (8) 8 (18) 
Thomsen et al. Plosone 2016 
Grade 1 HE patients have more immune 
dysfunction 
  
  
Unimpaired 
n=23 
 
mHE 
n=39 
 
Grade 1 HE 
n=44 
 
P-value 
 
 
Bacterial DNA n (%) 
 
5 (22) 
 
14 (36) 
 
25 (57) 
 
P=0.01 
 
Neut. resp. burst (%) 
 
13 ± 11 
 
13 ± 14 
 
22 ± 22 
 
P=0.03 
 
Phagocytosis (GMFI) 
 
84 ± 15 
 
81 ± 13 
 
78 ± 10 
 
P=0.16 
 
Cause or Effect? 
Thomsen et al. Plosone 2016 
Overt Hepatic Encephalopathy 
Is there need for a Type D 
EASL/AASLD Concensus. JHEP 2014 
Adapted from Jalan et al. Gastro 2014 2015 
The severity of HE is associated with 
different short and medium term mortality 
Adapted from Cordoba J et al. J Hepatol 2014;60:275–81 
The presence of ACLF alters the natural 
history of Hepatic Encephalopathy 
*p-value comparing presence vs absence of HE in patients without ACLF  
**p-value comparing presence vs absence of HE in patients with ACLF 
Competing risk assessment 
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Inflammation is a key factor distinguishing HE with 
ACLF vs HE without ACLF? 
Variable HE [No ACLF] 
[n=286] 
HE [ACLF] 
[n=174] 
Inflammatory Markers 
 
   White Cell count 
   CRP 
 
 
5.7 (4.2-8) 
13 (5-31) 
 
 
8.9 (5.8-13.7)*** 
32 (16-60)*** 
Adapted from Cordoba J et al. J Hepatol 2014;60:275–81 
Inflammation worsens 
Brain Swelling during 
Hyperammonemia but 
anatomical break down 
of Blood-Brain Barrier 
was NOT observed 
Are they neuropathologically different? 
What is the pathophysiological basis of 
HE in ACLF in humans? 
Prospective Study in ICU admitted patients 
with ACLF with an without HE 
• N=101 
• HE graded using West Haven cirteria 
• Overt HE: Defined as Grade 2 or more 
 
• Patients monitored 
– Sequential arterial ammonia 
– Inflammatory markers 
– Reverse jugular catheter to monitor oxygen saturation 
• Standard of care defined 
Sawhney et al. Liver Transplantation 2016 
The presence of HE determines the risk of death 
in ACLF patients studied prospectively (n=101) 
Sawhney et al. Liver Transplantation 2016 
Ammonia levels in overt HE (likely no ACLF) 
Ong et al. Am J Med 2003 
Ammonia levels were an independent predictor of severity of HE 
What about patients with ACLF? 
Sawhney et al. Liver Transplantation 2016 
Inflammation (WCC) 
Sawhney et al. Liver Transplantation 2016 
In ACLF and Brain oxygenation 
Sawhney et al. Liver Transplantation 2016 
The severity of hyperammonemia and jugular 
venous oxygen saturation determines risk of HE 
Sawhney and Holland-Fischer et al. AASLD 2014 
Pathophysiology of HE in ACLF 
HE 
severity
in ACLF 
 
 
Ammonia 
Inflammation 
Cerebral 
Oxygenation 
Sawhney et al. Liver Transplantation 2016 
Liver Injury 
Acute Chronic 
Acute Liver Failure Cirrhosis 
Portosystemic shunt 
(+/-) 
Type A Type B Type C 
ACLF 
Inflammation 
+ Organ Failure 
?Type D  
Where would the Type D fit in? 
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The Ammonia Story of Hepatic Encephalopathy 
Neuropathology 
Astrocyte Dysfunction and swelling 
Astrocyte Swelling vs 
Shrinkage  
Involvement of the 
Ammonia transporter 
NKCC1 (Thrane et al. Nature Medicine, 2013; 
19, 1643–1648) 
Hadjihambi, Rose and Jalan 
Hepatology 2014 
• >98% of ammonia 
present as NH4+ 
 
• NH4+ is capable 
crossing all 
phospholipid cell 
membranes through K+ 
channels 
SIRS* 
score 
0 
I 
II 
III 
IV 
Maximum Coma Grade 
I II III IV ICP 
42 29 29 47 17 
66 34 28 46 30 
0 40 20 56 35 
0 0 47 100 72 
0 0 0 84 65 
Inflammation and Encephalopathy 
Rolando et al, Hepatology 32, 734, 2000 
* On admission 
Resolution of infection 
24-36hr 
Inclusion into study Discharge 
Admission with infection 
 Resuscitate 
 Start antibiotics 
 Induce hyperammonemia 
Measure changes in neuropsychometry 
Journal of Hepatology 40 (2004) 247–254 
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Ammonia and Inflammation: 
Ammonia induced Brain edema is reduced in TLRKO 
Sharifi et al. AASLD 2014 
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Brain Flux of Pro-Inflammatory Cytokines 
ICP: Uncontrolled during patient FU 
Wright et al. Metab Brain Dis, 2007 
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NH3 Liver Disease 
HE 
SEPSIS 
Hypothesis 
Ammonia induces spontaneous respiratory burst 
through effects on p38 MAP kinase pathway 
 p38 antagonist: 10 µM SB203580 
Shawcross and Jalan et al. Hepatology 2007 
NH3 Liver Disease 
HE 
SEPSIS 
Hypothesis 
Can Hepatic Encephalopathy produce 
Immune Failure? 
Prass et al. J Exp Med. 2009 Sep 1;198(5):725-36.  
Due to apoptotic loss of 
Lymphocytes 
 
Shift from Th-1 to Th-2 
Phenotype 
Reversed by inhibition of 
Sympathetic System 
García-Martinez R. et al 2011 
Episodes of HE lead to neurodegeneration 
What is the mechanism? 
Expression of 
Serpin-1, a marker of 
senescence is 
increased in HE 
Cortex Cerebellum 
Hippocampus 
Oria et al. EASL 2014 
Therapeutic Approaches 
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BRAIN 
LIVER 
Glutamine KIDNEY 
MUSCLE 
GUT NH3 
Urea 
CIRRHOSIS 
Where is Ammonia metabolised in Liver 
Failure patients 
Shawcross and Jalan, Lancet 2005 
Therefore, new target organs for reducing 
ammonia  
• GUT 
• Kidneys 
• Muscle 
BRAIN 
LIVER 
Glutamine KIDNEY 
MUSCLE 
GUT NH3 
Urea 
CIRRHOSIS 
Glycerol Phenylbutyrate works by 
removing Glutamine 
Shawcross and Jalan, Lancet 2005 
How does Ornithine Phenylacetate work? 
Ornithine 
Phenylacetate 
Phosphate-activated  
glutaminase (PAG) 
(intestine, kidney) 
Glutamine 
NH4+ 
PAG Glutamate 
+ 
Phenylacetylglutamine Excreted in the urine  
Established treatment for 
hyperammonemia in patients with urea-
cycle disorders 
Muscle glutamate   =      GS activity   =      Muscle glutamine 
Muscle 
1 
2 
X 
NH4+ 
Treatment of hepatic encephalopathy 
 
 
 • Primary Prophylaxis 
• Secondary Prophylaxis 
• Treatment of the Acute episode 
Can we predict which patients with 
cirrhosis will develop HE and can 
the first episode be prevented? 
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Short-short or short-long 
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Romero-Gomez M et al. Ann Intern Med 2010;153:281–88 
Secondary Prophylaxis 
  
Lactulose for Secondary Prophylaxis 
Gastroenterology, 2009;137:885–91. 
Follow-up (months) 
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Probability of breakthrough hepatic encephalopathy 
Patients at risk 
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Placebo 
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Placebo (n=64) 
Lactulose (n=61) 
Rifaximin for Secondary Prophylaxis of HE: 
Recurrence 
 58% risk reduction (NNT = 4 over 6 months) 
Bass et al, N Engl J Med, 2010;362:1071–81. 
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p<0.001, HR 0.42 (95% CI, 0.28–0.64) 
Patients (%) 
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randomization 
Hazard ratio with rifaximin, 0.42  
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Time to HE event. The time to the first HE event over time is depicted for all patients (top panel; n=178), in patients 
not on rifaximin at baseline (middle panel; n=119), and in patients on rifaximin at baseline (bottom panel; n=59) 
Rockey D et al. Hepatology 2014;59:1073–83 
AMMONIA Baseline Treatment* 
Placebo 54 (34) umol/L 58 umol/L/wk 
GPB 48 (35) umol/L 46 umol/L/wk 
Glycerol phenylbutyrate reduces ammonia 
and prevents HE 
Treatment of the Acute Episode 
Treat precipitating event 
Nutrition 
Clean Bowel 
Treat precipitating factors 
Reduce ammonia: GPB; OP 
 
 In patients in whom there is no response? 
 Albumin Dialysis 
Low protein diet? 
Normal protein diet for episodic HE: results of a randomised study 
Cordoba et al. J of Hepatol 
• Outcome of HE was no 
different. 
  
• Protein synthesis was 
similar. 
 
• Those on the low-
protein diet group 
showed higher protein 
breakdown. 
Lactulose vs Polyethylene Glycol 3350-Electrolyte Solution for Treatment of Overt 
Hepatic Encephalopathy: The HELP Randomized Clinical Trial 
Rahimi et al. JAMA Intern Med. 2014;174(11):1727-1733. 


OCR-002 vs Standard of Care 
Courtesy: Genesca et al. 
Leckie, Davies and Jalan GASTROENTEROLOGY 2012;142:690–699 
J Hepatol 2013 

MARS Rx was significantly better 
Survival 
 
2 and 4 week survival were 
significantly greater in the 
responders compared with 
non-responders 
Hassanein et al. Hepatology 2007 
Hepatic Encephalopathy 
Minimal Overt 
Current 
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Summary 
Summary 
• Classification of HE 
– Covert HE is a heterogenous entity  
– HE in ACLF should be classified separately 
• The mechanisms of the deleterious effects of 
ammonia are being redefined 
– Ammonia and inflammation are synergistic in causing HE 
– Both are targets of therapy 
• HE is not reversible and efforts to prevent 1st and 
recurrent episodes is urgently needed 
• New therapeutic strategies for HE are emerging 
– More clinical trial data are needed 
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